| 000 | 01303 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250512005824.0 | ||
| 264 | 0 | _c19891102 | |
| 008 | 198911s 0 0 eng d | ||
| 022 | _a0160-9289 | ||
| 024 | 7 |
_a10.1002/clc.4960120904 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMann, D L | |
| 245 | 0 | 0 |
_aNeurohumoral activation in congestive heart failure: a double-edged sword? _h[electronic resource] |
| 260 |
_bClinical cardiology _cSep 1989 |
||
| 300 |
_a485-90 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBed Rest |
| 650 | 0 | 4 |
_aCatecholamines _xphysiology |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aHeart Failure _xetiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMyocardium _xpathology |
| 650 | 0 | 4 | _aNecrosis |
| 650 | 0 | 4 | _aNeurotransmitter Agents |
| 650 | 0 | 4 |
_aNorepinephrine _xadverse effects |
| 650 | 0 | 4 |
_aSympathomimetics _xadverse effects |
| 700 | 1 | _aCooper, G | |
| 773 | 0 |
_tClinical cardiology _gvol. 12 _gno. 9 _gp. 485-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/clc.4960120904 _zAvailable from publisher's website |
| 999 |
_c2577382 _d2577382 |
||